By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
| Currency | US Dollars |
| Share Price | $ 175.84 |
| Change Today | $ -4.60 |
| % Change | -2.55 % |
| 52 Week High | $182.09 |
| 52 Week Low | $118.84 |
| Volume | 1,506,685 |
| Shares Issued | 145.80m |
| Market Cap | $25,638m |
| RiskGrade | 259 |
| Strong Buy | 8 |
| Buy | 6 |
| Neutral | 20 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 34 |

| Time | Volume / Share Price |
| 15:59 | 100 @ $175.81 |
| 15:59 | 100 @ $175.82 |
| 15:59 | 200 @ $175.85 |
| 15:59 | 100 @ $175.94 |
| 15:59 | 140 @ $175.80 |
You are here: research